Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Gilead Sciences
(NQ:
GILD
)
63.50
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, May 29, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Gilead Sciences
< Previous
1
2
3
4
5
6
7
8
9
...
30
31
Next >
EXCLUSIVE: The 'Buy Everything' Market Is Over: Synopsys-Ansys Merger Provides Fertile Ground For This Stock Picker
January 18, 2024
The "buy everything" sentiment that powered equity indices higher last quarter is over. It's a stock picker's market, Marc Chaikin says.
Via
Benzinga
AbbVie, Arch Capital, Gilead Sciences And A Telecom Giant On CNBC's 'Final Trades'
January 18, 2024
On CNBC’s "Halftime Report Final Trades," Rob Sechan of NewEdge Wealth said Gilead Sciences, Inc.
Via
Benzinga
$1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth This Much Today
January 12, 2024
Via
Benzinga
AbbVie's Strategic Move: ImmunoGen Acquisition Triggers Golden Cross, Yet Valuation Caution Remains
January 11, 2024
AbbVie Inc (ABBV) stock is up 15% since acquiring ImmunoGen, but past Golden Cross rallies haven't sustained. With high valuation and competition, investors may want to wait for a pullback.
Via
Benzinga
Gilead’s Quiet Revolution: Is GILD the Next Big Stock to Soar?
January 10, 2024
While Wall Street obsesses over weight-loss drugs, Gilead Sciences is working on life-saving treatments and GILD stock looks ready to rally.
Via
InvestorPlace
NASDAQ:GILD is probably undervalued for the fundamentals it is displaying.
January 04, 2024
GILEAD SCIENCES INC (NASDAQ:GILD) is an undervalued gem with solid fundamentals.
Via
Chartmill
(GILD) - Analyzing Gilead Sciences's Short Interest
January 03, 2024
Via
Benzinga
$100 Invested In This Stock 20 Years Ago Would Be Worth $1,100 Today
December 25, 2023
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
January 10, 2024
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
January 08, 2024
Via
Benzinga
Nasdaq 100 Snaps Longest Negative Streak In 14 Months As Tech Stocks Find Relief On Mixed Data
January 05, 2024
The Nasdaq 100 ended the first week of 2024 on a positive note, ending a five-session losing streak, despite volatile trading and conflicting economic data.
Via
Benzinga
This Analyst Downgrades Bristol-Myers Squibb, Cautions Amid Product Launch And Revenue Concerns
January 03, 2024
BofA Securities downgraded Bristol-Myers Squibb & Co (NYSE: BMY), noting that initially, the analyst believed that Bristol's loss of exclusivity (LOEs) for drugs like Eliquis and Opdivo was widely...
Via
Benzinga
A Look Into Gilead Sciences Inc's Price Over Earnings
December 22, 2023
Via
Benzinga
(GILD) - Analyzing Gilead Sciences's Short Interest
December 18, 2023
Via
Benzinga
Nasdaq 100 Alert: 7 Undervalued Tech Stocks Ready to Rocket in 2024
January 03, 2024
Despite the gains of last year there are still many undervalued tech stocks on the Nasdaq 100 waiting to explode higher in 2024
Via
InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
January 02, 2024
Via
Benzinga
The 500 Top Stocks to Buy for 2024, Ranked by AI
December 29, 2023
These are the very best stocks to buy for 2024 for any investor, according to Tom Yeung's MarketMasterAI system.
Via
InvestorPlace
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
December 22, 2023
Each week, Benzinga’s Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks that are just under the surface and warrant attention.
Via
Benzinga
3 Biotech Stocks to Buy in the TradeSmith ‘Green Zone’
December 21, 2023
It's now time to take a look at these three biotech stocks to buy, as each one is currently within TradeSmith's "Green Zone."
Via
InvestorPlace
Why Is Immunotherapy-Focused Hookipa Pharma Stock Soaring Today?
December 21, 2023
Gilead Sciences Inc (NASDAQ: GILD) announced on Thursday that it has purchased 15 million shares of HOOKIPA Pharma Inc (NASDAQ: HOOK) for approximately $21.25 million,
Via
Benzinga
Why Is Hookipa Pharma (HOOK) Stock Up 81% Today?
December 21, 2023
Hookipa Pharma stock is rising higher on Thursday as investors react to a purchase agreement for 15 million shares of HOOK.
Via
InvestorPlace
RedHill's Investigational COVID-19 Drugs Combined With Gilead's Show Effect Against Ebola
December 20, 2023
RedHill Biopharma Ltd (NASDAQ: RDHL) says opaganib and RHB-107 (upamostat) demonstrated robust synergistic effects when combined individually with Gilead Sciences Inc (NASDAQ: GILD) Veklury...
Via
Benzinga
Exposures
COVID-19
QQQ And QQQM ETFs Top Gainers And Laggards Of 2023
December 20, 2023
This article will look at the top gainers and laggards of the two popular ETFs, which have over $17 billion and $223 billion assets, respectively. The two funds are similar, with the only difference...
Via
Talk Markets
Topics
ETFs
Why Compugen Shares Are Trading Higher By Over 200%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
December 19, 2023
Shares of Compugen Ltd. (NASDAQ: CGEN) shares rose sharply during Tuesday’s session after Gilead announced an agreement with the company to exclusively license its novel pre-clinical immunotherapy...
Via
Benzinga
Why Is Cancer Immunotherapy-Focused Compugen Stock Is Trading Higher Today?
December 19, 2023
Gilead Sciences Inc (NASDAQ: GILD) announced an agreement with Compugen Ltd (NASDAQ: CGEN) to license its pre-clinical antibody program against IL-18 binding protein exclusively, including the
Via
Benzinga
Why Is Compugen (CGEN) Stock Up 189% Today?
December 19, 2023
Compugen stock is up on Tuesday as investors in CGEN shares react to an exclusive licensing agreement with Gilead Sciences.
Via
InvestorPlace
Patients Regain Weight After They Quit Using Ozempic Rival Zepbound. Here's Why That Makes Eli Lilly Stock an Even Better Buy.
December 16, 2023
Lilly's weight loss drug appears to be on the way to becoming a megablockbuster.
Via
The Motley Fool
Pharma’s Frontline: 3 Stocks Driving Revolutionary Drug Development
December 15, 2023
These pharma stock leaders offer revolutionary treatments that could change the world of medicine (and investor's portfolios) for the better.
Via
InvestorPlace
NASDAQ:GILD is probably undervalued for the fundamentals it is displaying.
December 12, 2023
Investors should take notice ofGILEAD SCIENCES INC (NASDAQ:GILD)—it offers a great deal for the fundamentals it presents.
Via
Chartmill
A Bull Market Is Coming: 1 Stock That Could Rocket 219% Higher in 2024, According to Wall Street
December 12, 2023
There's a huge gap between what the stock market and Wall Street analysts have to say about this often-overlooked growth stock.
Via
The Motley Fool
< Previous
1
2
3
4
5
6
7
8
9
...
30
31
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.